skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tackling obesity: new therapeutic agents for assisted weight loss

Review

(3737) Views  (1639) Full article downloads

Authors: JG Karam, SI McFarlane

Published Date April 2010 Volume 2010:3 Pages 95 - 112
DOI: http://dx.doi.org/10.2147/DMSO.S6552

JG Karam1, SI McFarlane2

1SUNY-Downstate-Kings County Hospital, Brooklyn, NY, USA, Maimonides Medical Center, Brooklyn, NY, USA; 2Division of Endocrinology, College of Medicine, State University of New York-Downstate Medical Center, New York, USA

Abstract: The pandemic of overweight and obesity continues to rise in an alarming rate in western countries and around the globe representing a major public health challenge in desperate need for new strategies tackling obesity. In the United States nearly two thirds of the population is overweight or obese. Worldwide the number of persons who are overweight or obese exceeded 1.6 billion. These rising figures have been clearly associated with increased morbidity and mortality. For example, in the Framingham study, the risk of death increases with each additional pound of weight gain even in the relatively younger population between 30 and 42 years of age. Overweight and obesity are also associated with increased co-morbid conditions such as diabetes, hypertension and cardiovascular disease as well as certain types of cancer. In this review we discuss the epidemic of obesity, highlighting the pathophysiologic mechanisms of weight gain. We also provide an overview of the assessment of overweight and obese individuals discussing possible secondary causes of obesity. In a detailed section we discuss the currently approved therapeutic interventions for obesity highlighting their mechanisms of action and evidence of their efficacy and safety as provided in clinical trials. Finally, we discuss novel therapeutic interventions that are in various stages of development with a special section on the weight loss effects of anti-diabetic medications. These agents are particularly attractive options for our growing population of obese diabetic individuals.

Keywords: obesity, assisted weight loss, therapy






 

Other articles by Professor Samy McFarlane



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
The economic impact of obesity in the United States
Everolimus-eluting stents: update on current clinical studies
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio